2,805 reports of this reaction
4.7% of all OXCARBAZEPINE reports
#2 most reported adverse reaction
SEIZURE is the #2 most commonly reported adverse reaction for OXCARBAZEPINE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,805 FDA adverse event reports linking OXCARBAZEPINE to SEIZURE. This represents approximately 4.7% of all 60,018 adverse event reports for this drug.
OXCARBAZEPINE has an overall safety score of 85 out of 100. Patients taking OXCARBAZEPINE who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is moderately reported among OXCARBAZEPINE users, representing a notable but not dominant share of adverse events.
In addition to seizure, the following adverse reactions have been reported for OXCARBAZEPINE:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 2,805 FDA reports for OXCARBAZEPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 4.7% of all adverse event reports for OXCARBAZEPINE, making it one of the most commonly reported side effect.
If you experience seizure while taking OXCARBAZEPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.